Aoki Yoichi, Tanaka Kenichi
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi dori, Niigata 951-8510, Japan.
Expert Rev Anticancer Ther. 2002 Feb;2(1):73-82. doi: 10.1586/14737140.2.1.73.
Despite remarkable improvement in clinical management, the survival of cervical cancer patients has shown only minor progress in the last decade, particularly in patients with advanced and high-risk disease. Multimodal treatment option has been investigated, such as the concurrent use of chemotherapy and radiation, neoadjuvant chemotherapy and radical hysterectomy, or neoadjuvant chemotherapy followed by radiotherapy. Recently, a flow of randomized clinical trials have demonstrated a benefit from the concurrent chemoradiation for the treatment of the cancer of the cervix. This review will summarize the role and benefit of neoadjuvant chemotherapy in combination with sequential or concurrent radiotherapy and radical surgery for treatment of cervical cancer.
尽管临床管理有了显著改善,但在过去十年中,宫颈癌患者的生存率仅取得了微小进展,尤其是晚期和高危疾病患者。人们已经研究了多模式治疗方案,例如化疗与放疗同时使用、新辅助化疗与根治性子宫切除术,或新辅助化疗后进行放疗。最近,一系列随机临床试验表明同步放化疗对宫颈癌治疗有益。本综述将总结新辅助化疗联合序贯或同步放疗及根治性手术在宫颈癌治疗中的作用和益处。